Linked e-resources
Details
Table of Contents
Foreword; Preface; Contents; 1 What Is Comorbidity?; Abstract; 1.1 What Is Comorbidity?; 1.2 The Evolution of the Concept of Comorbidity; 1.3 Diagnostic-Based Risk (or Case-Mix) Adjustment Systems; 1.4 Clinically-Based Comorbidity Indices; 1.5 Recent Evolution Relating to the Concept of Comorbidity; 1.6 Constructs Related to Comorbidity; 1.7 Multimorbidity; 1.8 Functional (or Performance) Status; 1.9 Disability; 1.10 Allostatic Load; 1.11 Frailty; 1.12 Burden of Disease/Illness; 1.13 Complexity; 1.14 How Are the Comorbidity-Related Constructs Linked?
1.15 Why Should We Focus on Comorbidity in Cancer?1.16 How Common Is Comorbidity in Cancer?; 1.17 Cancer, Comorbidity and Disparity; 1.18 Why Do Cancer and Comorbidity Coexist?; 1.18.1 Common Conditions Occur Commonly; 1.18.2 Cancer and Comorbid Conditions Share Many Common Risk Factors; 1.18.3 Comorbidity May Increase or Decrease Predisposition to Cancer; 1.18.4 Treatment for Comorbidity May Increase or Decrease the Risk of Cancer; 1.18.5 Treatment for Cancer May Cause or Exacerbate Comorbidity; 1.18.6 There May Be Common Genetic or Physiological Pathways Between Cancer and Comorbidities
1.19 Future Directions for Practice or ResearchReferences; 2 How Do We Measure Comorbidity?; Abstract; 2.1 Introduction; 2.2 Individual Conditions or Counts of Conditions; 2.3 Content and Face Validity; 2.4 Criterion Validity; 2.4.1 Concurrent; 2.4.2 Predictive; 2.5 Reliability; 2.6 Feasibility; 2.7 Organ-Based Approaches; 2.8 Content and Face Validity; 2.9 Criterion Validity; 2.9.1 Concurrent; 2.9.2 Predictive; 2.10 Reliability; 2.11 Feasibility; 2.12 Weighted Indices; 2.13 Content and Face Validity; 2.14 Criterion Validity; 2.14.1 Concurrent; 2.14.2 Predictive; 2.15 Reliability
2.16 Feasibility2.17 Other Approaches to Measuring Comorbidity in Cancer Populations; 2.18 Content and Face Validity; 2.19 Criterion Validity; 2.19.1 Concurrent; 2.19.2 Predictive; 2.20 Reliability; 2.21 Feasibility; 2.22 So Which Index Is Best?; 2.23 Future Directions for Practice or Research; References; Further reading; 3 Cancer, Chronic Conditions and Social Disadvantage-The Perfect Storm; Abstract; 3.1 Introduction; 3.2 The Theory of Social Quality as a Conceptual Framework for Understanding Socio-economic Status
3.3 The Role of Healthcare Services in Addressing Social Quality for Vulnerable Groups3.4 The Need for More Equitable Access to Healthcare Services for Vulnerable Groups; 3.5 Inequity, Inequality and Disparity: What Is the Difference and How Do We Measure 'Equity'?; 3.6 Culturally Diverse Patients in the Context of Cancer Care and Chronic Disease; 3.6.1 Cultural Diversity and Its Challenges Within the USA, UK, Canada and Australia; 3.7 Ethnicity and Cancer Care; 3.7.1 Communication with Culturally Diverse Patients in Cancer Care Settings
1.15 Why Should We Focus on Comorbidity in Cancer?1.16 How Common Is Comorbidity in Cancer?; 1.17 Cancer, Comorbidity and Disparity; 1.18 Why Do Cancer and Comorbidity Coexist?; 1.18.1 Common Conditions Occur Commonly; 1.18.2 Cancer and Comorbid Conditions Share Many Common Risk Factors; 1.18.3 Comorbidity May Increase or Decrease Predisposition to Cancer; 1.18.4 Treatment for Comorbidity May Increase or Decrease the Risk of Cancer; 1.18.5 Treatment for Cancer May Cause or Exacerbate Comorbidity; 1.18.6 There May Be Common Genetic or Physiological Pathways Between Cancer and Comorbidities
1.19 Future Directions for Practice or ResearchReferences; 2 How Do We Measure Comorbidity?; Abstract; 2.1 Introduction; 2.2 Individual Conditions or Counts of Conditions; 2.3 Content and Face Validity; 2.4 Criterion Validity; 2.4.1 Concurrent; 2.4.2 Predictive; 2.5 Reliability; 2.6 Feasibility; 2.7 Organ-Based Approaches; 2.8 Content and Face Validity; 2.9 Criterion Validity; 2.9.1 Concurrent; 2.9.2 Predictive; 2.10 Reliability; 2.11 Feasibility; 2.12 Weighted Indices; 2.13 Content and Face Validity; 2.14 Criterion Validity; 2.14.1 Concurrent; 2.14.2 Predictive; 2.15 Reliability
2.16 Feasibility2.17 Other Approaches to Measuring Comorbidity in Cancer Populations; 2.18 Content and Face Validity; 2.19 Criterion Validity; 2.19.1 Concurrent; 2.19.2 Predictive; 2.20 Reliability; 2.21 Feasibility; 2.22 So Which Index Is Best?; 2.23 Future Directions for Practice or Research; References; Further reading; 3 Cancer, Chronic Conditions and Social Disadvantage-The Perfect Storm; Abstract; 3.1 Introduction; 3.2 The Theory of Social Quality as a Conceptual Framework for Understanding Socio-economic Status
3.3 The Role of Healthcare Services in Addressing Social Quality for Vulnerable Groups3.4 The Need for More Equitable Access to Healthcare Services for Vulnerable Groups; 3.5 Inequity, Inequality and Disparity: What Is the Difference and How Do We Measure 'Equity'?; 3.6 Culturally Diverse Patients in the Context of Cancer Care and Chronic Disease; 3.6.1 Cultural Diversity and Its Challenges Within the USA, UK, Canada and Australia; 3.7 Ethnicity and Cancer Care; 3.7.1 Communication with Culturally Diverse Patients in Cancer Care Settings